#USA #New York #Securities Fraud #Pomerantz LLP #ADMA Biologics

Pomerantz Law Firm Investigates ADMA Biologics Investors' Claims

On April 16, 2026, Pomerantz LLP announced its investigation into potential claims made on behalf of investors in ADMA Biologics, Inc. (NASDAQ: ADMA). This action comes amid serious allegations regarding the company's business practices, including accusations of securities fraud.

The firm urges investors who may have been impacted to contact Danielle Peyton, an attorney at Pomerantz, to discuss their rights and the potential for joining a class action lawsuit. The firm has built a strong reputation for advocating for corporate governance and investor protection, especially in cases involving fraud and misconduct.

The Allegations

The investigative interest was piqued following a short report released by Culper Research on March 24, 2026. This report made shocking claims about ADMA’s reported growth, alleging that it was largely fictitious and driven by what it termed a “de facto channel stuffing scheme.” Furthermore, it indicated that an undisclosed related-party distributor was manipulating sales reports.

According to Culper Research, ADMA's revenues reportedly declined by 3% in 2025, contrary to the reported growth of over 20%. This level of discrepancy raises significant concerns about the integrity of financial reporting at ADMA.

On the day the report was released, ADMA's stock plummeted by $2.26, marking a substantial drop of 16.63%, closing at $11.33 per share. This decline highlights the immediate impact that such allegations can have on investor confidence and market behavior.

Following this initial drop, Cantor Fitzgerald issued a downgrade for ADMA on March 26, 2026. The downgrade cited dissatisfaction with the Company's lack of clear responses addressing the allegations in the Culper report. Cantor Fitzgerald deemed the company's rebuttal to be insufficient, lacking the specific insights that investors were seeking. Consequently, ADMA's share price suffered further, falling an additional $1.34 (13.91%) to close at $8.29.

About Pomerantz LLP

Pomerantz LLP is a distinguished law firm based in multiple cities including New York, Chicago, and London, recognized for its expertise in corporate, securities, and antitrust class litigation. Established by Abraham L. Pomerantz, a pioneer in securities class actions, the firm has a rich legacy of securing billion-dollar settlements for investors. They continue to advocate for victims of corporate fraud and protect shareholder rights, consistently striving for justice in the complex environment of financial markets.

The firm intends to thoroughly investigate the claims regarding ADMA and could potentially lead a class action lawsuit if sufficient evidence is found. They encourage affected investors to come forward, as a collective voice can have a powerful impact.

As more details surface about ADMA's financial practices and the validity of the growth reporting, investors are left to grapple with the implications of these findings. Transparency and accountability in corporate governance are essential to maintaining investor trust, and the outcomes of this investigation are likely to reverberate across the market.

Anyone with information about the issues surrounding ADMA Biologics is encouraged to reach out to Pomerantz LLP. As always, potential investors should do their due diligence before engaging with any company that may be facing legal scrutiny.